IDeA Networks of Biomedical Research Excellence

Leaders in Breast and Lung Cancer treatment join SystImmune Inc's Clinical Science Advisory Committee

Retrieved on: 
Wednesday, April 26, 2023
IDeA Networks of Biomedical Research Excellence, TNBC, Memorial Sloan Kettering Cancer Center, Triple-negative breast cancer, Therapy, SPORE, CDK, Cancer and Leukemia Group B, Belfer Center for Science and International Affairs, Survival, Cancer, Lung cancer, Woman, MMSC, Research, NSCLC, CMO, CALGB, Immunotherapy, Biomarker, Associate, Oncology, Harvard Medical School, CSAC, Patient, UCSF, Breast cancer, Division, Susan, EGFR, MSK, Biology, ADC, Haematopoietic system, Antibody-drug conjugate, George M. Low Center for Industrial Innovation, Disease, Dana–Farber Cancer Institute, Medical device, Birth control, Medical imaging, Sacituzumab govitecan, Medicine

Dr. Rugo and Dr. Tolaney bring more than 40 years combined of breast cancer clinical experience in early oncology research and global drug development.

Key Points: 
  • Dr. Rugo and Dr. Tolaney bring more than 40 years combined of breast cancer clinical experience in early oncology research and global drug development.
  • They have led high-profile clinical programs, including the development of Trodelvy (sacituzumab govitecan-hziy), the most recent drug approved for the treatment of triple-negative breast cancer (TNBC).
  • Their expertise will guide SystImmune in the advancement of its ADC pipeline into breast cancer.
  • Dr. Rugo is the director of UCSF's breast cancer clinical trials program and the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late-stage breast cancer.

Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero

Retrieved on: 
Wednesday, April 12, 2023
SAB, San Francisco Bay Area, Special Program of Assisted Reproduction, AACR, SPORE, Science and technology in Asia, Vall, ESMO, American Society of Clinical Oncology, Cancer, American Association for Cancer Research, United States Air Force Scientific Advisory Board, Research, Oncology, Signal transduction, European Society for Medical Oncology, Cantley, Ioan Totu, AGIO, Harvard Medical School, ASCO, PI3K, United Nations Scientific Committee on the Effects of Atomic Radiation, Cell biology, Patient, UCSF, Drug discovery, Society, Agios Pharmaceuticals, IDeA Networks of Biomedical Research Excellence, Breast cancer, Disease, Pharmaceutical industry, Antibiotics, Medical device

To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.

Key Points: 
  • To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.
  • They include:
    Dr. Lewis Cantley : Dr. Cantley's work has helped define the field of signal transduction, and he notably discovered the PI3K pathway and its role in cancer.
  • "I am excited to join the Scientific Advisory Board of Totus Medicines.
  • The SAB advances Totus' efforts to continue to deliver unparalleled efficiency and accuracy with its groundbreaking drug discovery platform.

Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board

Retrieved on: 
Wednesday, March 1, 2023
Netherlands Cancer Institute, Immunotherapy, Cancer, Prostate cancer, DNA, University, Principal, Basic research, SAB, VISTA, Stomach cancer, Associate, Core, Fred Hutchinson Cancer Research Center, Research, University of Washington School of Medicine, Gastrointestinal cancer, Pacific Northwest, United States Department of Defense, National Cancer Institute, Biomarker, LAPS, Knight Cancer Institute, Patient, Esophageal cancer, Trial of the century, IDeA Networks of Biomedical Research Excellence, Cell, Clinical Cancer Research, OHSU, Ponce Health Sciences University, AACR, Oregon Health & Science University, United States Air Force Scientific Advisory Board, Oregon Health and Science University Center for Women's Health, Medical director, Development of the human body, ASCO, Gastrointestinal tract, Prostate, Medical device, Medical imaging, Kineta

to the company’s immuno-oncology focused Scientific Advisory Board (SAB).

Key Points: 
  • to the company’s immuno-oncology focused Scientific Advisory Board (SAB).
  • Dr. Chalabi and Dr. Yu will join Kineta’s SAB that includes Lisa Coussens, Ph.D., Michael Curran, Ph.D. and Patricia LoRusso, D.O.
  • “We are delighted to have Dr. Chalabi and Dr. Yu join Kineta's Scientific Advisory Board,” stated Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
  • “These experts will greatly complement our existing SAB and guide the company as we advance clinical development of KVA12123 in patients with advanced solid tumors.”
    Myriam Chalabi, M.D.

Caris' Precision Oncology Alliance Welcomes University of Iowa Holden Comprehensive Cancer Center

Retrieved on: 
Wednesday, November 16, 2022
Database, RNA, FACP, IDeA Networks of Biomedical Research Excellence, Faculty, MBA, Physician, University, SPORE, Industry, Cancer, American Securities, Research, Education, NCI, Intelligence, POA, Patient, DNA, Blood, Artificial intelligence, Diagnosis, Drug development, Protein, Holden, Disease, Pharmaceutical industry, Medical imaging

IRVING, Texas, Nov. 16, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that University of Iowa Holden Comprehensive Cancer Center has joined Caris' Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.

Key Points: 
  • IRVING, Texas, Nov. 16, 2022 /PRNewswire/ -- Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that University of Iowa Holden Comprehensive Cancer Center has joined Caris' Precision Oncology Alliance (POA).
  • Holden Cancer Center is Iowa's only NCI-designated comprehensive cancer center, and has held that designation since 2000.
  • "We're pleased to welcome Holden Cancer Center into the growing Caris Precision Oncology Alliance network," said Chadi Nabhan , M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance.
  • "Collaborating with top researchers, investigators, and physicians at the University of Iowa Cancer Center will lead to more cutting-edge precision oncology research that is destined to improve outcomes of all patients affected with cancer."

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Associate, NEW, Beth Israel Deaconess Medical Center, Tumor microenvironment, 2021 Essex County Council election, CGMP, GLOBE, Assistant professor, Webcast, Therapy, Division, CEO, Annual general meeting, Cone Health Women's Hospital, Hospital, Providence Saint Joseph Medical Center, Oncology, CSO, Harvard Medical School, Doctor of Philosophy, IDeA Networks of Biomedical Research Excellence, R, Hematology, Leadership, Society, SITC, Weill Cornell Medicine, Cancer, Mink, Vaccine, Pharmaceutical industry, Animal, Management, Score

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the third quarter 2022 and provided a corporate update.

Key Points: 
  • - R&D Day on November 10, 2022, from 4:00-6:00pm ET in Boston and via webcast
    NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc ., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the third quarter 2022 and provided a corporate update.
  • This progress is exemplified in the five upcoming presentations at this years SITC conference and our upcoming R&D Day.
  • Individuals interested in attending the event in-person should contact MiNK Therapeutics Investor Relations at [email protected].
  • We ended the third quarter 2022 with a cash balance of$24.2 million as compared to $38.9 millionatDecember 31, 2021.

New Medical Imaging Center for Translational Cancer Research Announced at The University of Oklahoma

Retrieved on: 
Tuesday, March 22, 2022
AME Publishing Company, Medical imaging, National, Diagnosis, Multimedia, Computer engineering, Research, School, Faculty, Hospital, CT, Neoplasm, Reading, Centers of Biomedical Research Excellence, Purdue University School of Electrical and Computer Engineering, Cancer, View, University of Oklahoma, Radiology, Artificial intelligence, Biomedical Research, Technology, NIH, Electricity, Index, Subjectivity, Oklahoma Center for the Advancement of Science and Technology, Center, COBRE, MRI, IDeA Networks of Biomedical Research Excellence, University, Pharmaceutical industry, Dropbox

NORMAN, Okla., March 22, 2022 /PRNewswire/ --The University of Oklahoma has received funding from the National Institutes of Health to establish the Oklahoma Center of Medical Imaging for Translational Cancer Research.

Key Points: 
  • NORMAN, Okla., March 22, 2022 /PRNewswire/ --The University of Oklahoma has received funding from the National Institutes of Health to establish the Oklahoma Center of Medical Imaging for Translational Cancer Research.
  • Bin Zheng , Ph.D., a professor and Oklahoma TSET Cancer Research Scholar in the Gallogly College of Engineering's School of Electrical and Computer Engineering, is leading the new center.
  • University of Oklahoma researchers are investigating multiple avenues to help improve medical imaging use in cancer detection, diagnosis and treatment.
  • "While there are other kinds of testing methods, like blood testing, imaging is the most commonly used by clinicians," Zheng said.

Respira Technologies, Inc. announces Jasjit S. Ahluwalia, MD, MPH, MS as Chair of the company's newly formed Scientific Advisory Board.

Retrieved on: 
Tuesday, January 18, 2022
Poseidon, Coronavirus Scientific Advisory Board (Turkey), COPD, Research, NDA, Nicotine, Technology, NIH, Diabetes, CADRE, Investigational New Drug, Mortality, Publication, Tobacco, Addiction, Disease, Harm reduction, National Institute on Minority Health and Health Disparities, Smoker, Science, CA, Brown University, IDeA Networks of Biomedical Research Excellence, Death, CEO, VMN, Health equity, IND, Center, Public health, Daněk, Center for Drug Evaluation and Research, View, Pain management, Smoking, Associate, COBRE, Multimedia, Compass rose, Centers of Biomedical Research Excellence, Smoking cessation, FDA, Pharmaceutical industry, Asthma

LOS ANGELES, Calif., Jan. 18, 2022 /PRNewswire/ -- Respira Technologies, Inc. (Los Angeles, CA) announced today, the formation of its Scientific Advisory Board and named Dr. Jasjit ("Jas") S. Ahluwalia as Chair of the newly formed advisory board.

Key Points: 
  • LOS ANGELES, Calif., Jan. 18, 2022 /PRNewswire/ -- Respira Technologies, Inc. (Los Angeles, CA) announced today, the formation of its Scientific Advisory Board and named Dr. Jasjit ("Jas") S. Ahluwalia as Chair of the newly formed advisory board.
  • Danek added, "We are thrilled to name Dr. Ahluwalia as Chair and the founding member of our Scientific Advisory Board.
  • He represents one of the best and brightest scientific minds with decades of experience in studying nicotine addiction and cessation.
  • Respira is backed by venture firms: Blue Ledge Capital, Compass Rose, DG Ventures, Evolution VC Partners and Poseidon Asset Management.

Apexigen To Host Key Opinion Leader Webinar on Sotigalimab in Post-Anti-PD-(L)1 Melanoma

Retrieved on: 
Tuesday, November 9, 2021
SITC, Environment and Communications Committee (Iceland), IDeA Networks of Biomedical Research Excellence, Yale Cancer Center, SAN, Faculty, Yale School of Medicine, KOL, Society, Research, 2021 Essex County Council election, Renal cell carcinoma, SPORE, Yale school, Conference, GLOBE, Therapy, CD40, FC, Q&A, Toxicity, Oncology, Immunotherapy, Education, Patient, Prevalence, Melanoma, Pharmaceutical industry

SAN CARLOS, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced that it will host a key opinion leader (KOL) webinar on the therapeutic potential of sotigalimab in post-anti-PD-(L)1 melanoma, the Company’s lead immuno-oncology candidate, on Friday, November 19, 2021 at 11:00 a.m. ET. Sotigalimab is a potentially first-in-class and best-in-class CD40 agonist, with unique epitope specificity and Fc receptor engagement for optimal therapeutic effect and tolerability.

Key Points: 
  • Sotigalimab is a potentially first-in-class and best-in-class CD40 agonist, with unique epitope specificity and Fc receptor engagement for optimal therapeutic effect and tolerability.
  • The webinar will feature a presentation by KOL Harriet Kluger, M.D., from the Yale School of Medicine.
  • Dr. Kluger will discuss the current treatment landscape and unmet medical need in treating patients with post-anti-PD-(L)1 melanoma and the sotigalimab phase 2 data in post-PD-1(L)1 patients.
  • Dr. Kluger and Apexigens Chief Medical Officer, Frank Hsu, M.D., will also lead a discussion on the most recent Phase 2 sotigalimab melanoma data.